|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
These mid-caps are volatile, but a merger or major announcement could send them soaring.
The market is quietly holding up, and I'm not anticipating a major fade at this point.
Senior columnist Adam Feuerstein says the ASCO Cancer Conference is the next big thing in biotech.
These stocks don't seem to care about the gyrations of overheated algorithms and fearful shareholders.
We seem to be headed for frustrating action, and these stocks could buck the tide.
These speculative biotech issues have the power to defy gravity in the worst markets.